Investors in Nano-X Imaging (NNOX) can apply to lead a securities fraud class action before the August 11, 2026 deadline
Executive summary: Rosen Law Firm notified investors who bought Nano‑X Imaging (NASDAQ: NNOX) shares between March 31, 2025 and April 17, 2026 that they have until August 11, 2026 to seek appointment as lead plaintiff in a securities fraud class action. The choice of lead plaintiff influences case strategy, settlement leverage and potential recovery for affected shareholders.
Who is involved: Nano‑X Imaging Ltd., Rosen Law Firm, investors who held NNOX during the class period, and the federal court overseeing the suit.
Likely next: Investors will file lead plaintiff motions by Aug 11, 2026; the court will hold a hearing (likely early September) to appoint a lead plaintiff, after which discovery proceeds.
Rosen Law Firm issued a reminder that purchasers of NNOX shares between March 31, 2025 and April 17, 2026 have until August 11, 2026 to move for lead plaintiff status in a securities fraud class action. The notice repeats information previously disclosed in earlier alerts and does not allege new wrongdoing. It highlights the procedural step whereby the court will select a lead plaintiff to direct the litigation.
Timeline
- — NNOX Deadline: NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit (PR Newswire)
- — NNOX Deadline Alert: Levi & Korsinsky Reminds Nano-X Imaging Ltd. (NNOX) Investors of Securities Class Action Deadline on August 11, 2026 (PR Newswire)
- — NNOX Shareholder Alert: Nano-X Imaging Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm (PR Newswire)
- — NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit (PR Newswire)
Analysis — what this means
Likely next events
- August 11, 2026: Deadline for lead plaintiff motions in the NNOX securities fraud class action.
- Early September 2026: Expected court hearing to appoint lead plaintiff for the NNOX case.
- Q4 2026: Start of discovery phase if a lead plaintiff is appointed.
- Mid-2027: Potential settlement negotiations or trial proceedings.
Sectors affected
- Medical imaging technology
- Healthcare equipment
- NASDAQ‑listed securities
Regulatory implications
- SEC may scrutinize disclosures under Regulation FD.
- Private Securities Litigation Reform Act (PSLRA) governs the lead plaintiff selection process.
- If fraud is proven, NNOX could face civil penalties and injunctions.
Historical parallels
- Theranos securities fraud case (2018) where investors sued over false blood‑test claims.
- Luckin Coffee accounting scandal (2020) that triggered a class action over inflated sales.
Key entities
Sources
- NNOX Deadline: NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit — PR Newswire
- NNOX Deadline Alert: Levi & Korsinsky Reminds Nano-X Imaging Ltd. (NNOX) Investors of Securities Class Action Deadline on August 11, 2026 — PR Newswire
- NNOX Shareholder Alert: Nano-X Imaging Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm — PR Newswire
- NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit — PR Newswire
Related cases
- Nano-X Imaging faces lead plaintiff deadline as shareholder litigation over stock losses intensifies
- Pomerantz files class action against Nano-X Imaging alleging securities fraud tied to manufacturing risks and financial disclosures
- Investors can step forward as lead plaintiffs in a securities fraud class action against Nano-X Imaging over alleged misleading disclosures